Expert Review of Vaccines

Papers
(The median citation count of Expert Review of Vaccines is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States194
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey96
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic93
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response90
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China84
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 77
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy68
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?64
Indirect protection from rotavirus vaccines: a systematic review63
Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings61
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review57
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection55
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom52
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era50
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-202049
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China45
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness44
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo41
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children41
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study39
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis39
Microarray patches: scratching the surface of vaccine delivery38
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays37
The important lessons lurking in the history of meningococcal epidemiology37
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis37
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women35
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China35
Vaccines against leishmaniasis: using controlled human infection models to accelerate development34
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above34
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond33
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis33
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy32
Immunization in pregnancy to protect pregnant people and their newborns against COVID-1932
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion32
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative31
Cost-effectiveness of cell-based influenza vaccine in France31
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment31
TAK-003: development of a tetravalent dengue vaccine30
Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States29
COVID-19 vaccines approved in the European Union: current evidence and perspectives28
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany26
Looking to the future: is a universal coronavirus vaccine feasible?26
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan26
Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines26
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis26
COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 202125
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination25
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China25
Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges25
COVID-19 vaccine trials and sex-disaggregated data25
In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers25
Vaccines against mpox: MVA-BN and LC16m824
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China24
COVID-19 vaccination in pregnant and lactating women: a systematic review24
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect24
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population24
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia24
Self-controlled case series design in vaccine safety: a systematic review23
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru22
Travelers’ preferences for tick-borne encephalitis vaccination22
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems22
Adjuvant system AS01: from mode of action to effective vaccines21
An instrument to measure psychosocial determinants of health care professionals’ vaccination behavior: Validation of the Pro-VC-Be questionnaire21
Anti-neuraminidase immunity in the combat against influenza21
Vaccination policies for dentists and other dental professionals in Europe: a systematic report20
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o20
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China20
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines19
Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan19
The durability of vaccine-induced protection: an overview19
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children19
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine19
Suspended cell lines for inactivated virus vaccine production19
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination19
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease18
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study18
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories18
Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis18
Impact of rotavirus vaccination on diarrheal disease burden of children in South America17
The associations of geographic location and perceived risk of infection with the intentions to get vaccinated against COVID-19 in China17
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review17
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks17
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine17
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study17
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome16
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States16
Estimating the time required to reach HPV vaccination targets across Europe16
A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK16
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination16
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–201916
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?16
Eyedrop vaccination: an immunization route with promises for effective responses to pandemics16
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review16
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan16
Expert review on global real-world vaccine effectiveness against SARS-CoV-215
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses15
Next generation live-attenuated influenza vaccine platforms15
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study15
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study15
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs15
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine15
Correspondence on ‘Herpes Zoster and Simplex reactivation following COVID-19 vaccination’14
Development of a recombinant vaccine against human onchocerciasis14
COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey14
Have mRNA vaccines sentenced DNA vaccines to death?14
Lymphatic filariasis vaccine development: neglected for how long?14
Public health impact and return on investment of the pediatric immunization program in Poland14
Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?14
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older14
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza14
Making COVID-19 mRNA vaccines accessible: challenges resolved14
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era14
Health behaviors are largely not predictive of adverse events following influenza vaccination13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice13
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis13
Determinants of parental hesitancy to vaccinate their children against COVID-19 in China13
COVID-19 and vaccination: myths vs science13
Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage13
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations13
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines13
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients13
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution13
Vaccine for a neglected tropical disease Taenia solium cysticercosis: fight for eradication against all odds12
Repeated vaccination and ‘vaccine exhaustion’: relevance to the COVID-19 crisis12
Subolesin: a 20-year path from discovery to an effective tick vaccine12
Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons 12
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan12
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella12
An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants12
Vaccine clinical trials in low- and middle-income countries: a brief review of standard, newer and proposed approaches12
Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018–2024: a database study12
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data12
Emergence of mRNA vaccines in the management of cancer12
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions12
Nanovaccine: an emerging strategy12
Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh12
An overview: CRISPR/Cas-based gene editing for viral vaccine development12
Correction12
What are the challenges faced by COVID-19 vaccines?12
Vaccines against SARS-CoV-2 variants and future pandemics12
Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context11
Letter to the editor in response to: A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children11
Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines11
Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen11
Impact of a two-dose varicella immunization program on the incidence of varicella: a multi-year observational study in Shanghai, China11
Reply to: correspondence on “Herpes Zoster and Simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis​”11
Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States11
Sars-Cov-2 virus and vaccination; biological and statistical framework11
Recent advances in lipopolysaccharide-based glycoconjugate vaccines11
Understanding barriers to vaccination against invasive meningococcal disease: a survey of the knowledge gap and potential solutions11
A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson’s disease11
Assessment of the comprehensiveness of paediatric national immunisation programmes in Europe: expert validation and future perspectives11
Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand11
Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore11
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia10
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies10
The role of bactericidal and opsonic activity in immunity against Bordetella pertussis10
From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection10
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis10
Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines10
Health economic analyses of secondary vaccine effects: a systematic review and policy insights10
Research progress on immune mechanism and control strategy of dsRNA impurities in mRNA vaccine10
Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness10
Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses10
The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines10
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy10
Response to: “immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories”10
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant10
COVID-19 vaccine design and vaccination strategy for emerging variants10
Quantification methods for viruses and virus-like particles applied in biopharmaceutical production processes10
No association between enterovirus 71 (EV71) vaccination and risk of febrile seizures: a population-based near real-time surveillance study10
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan10
Delays in routine childhood vaccinations and their relationship with parental vaccine hesitancy: a cross-sectional study in Wuxi, China10
Adult vaccination against respiratory infections in Egypt: a review of expert opinions9
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands9
Respiratory syncytial virus infection and the need for immunization in Korea9
SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy9
Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study9
Tackling vaccine inequity in 2023: have we made progress?9
Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data9
Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire9
Examining the validity of the drivers of COVID-19 vaccination acceptance scale using Rasch analysis9
Risk of herpes zoster following mRNA COVID-19 vaccine administration9
Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity9
Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies9
Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin America countries9
A review of data systems for assessing the impact of HPV vaccination in selected high-income countries9
Approaches in broadening the neutralizing antibody response of the influenza vaccine9
Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review9
Combatting infectious diarrhea: innovations in treatment and vaccination strategies8
The broader benefits of vaccines: methodologies for inclusion in economic evaluation8
Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000-20208
Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward8
The quest for an HIV-1 vaccine: will mRNA deliver us from evil?8
COVID-19 vaccination hesitancy in Italian healthcare workers: a systematic review and meta-analysis8
No observable influence of COVID-19 inactivated vaccines on pregnancy and birth outcomes in the first trimester of gestation8
Global impact of delta plus variant and vaccination8
Vaccination against pertussis in Latin American preterm and low-birth weight infants: experts opinion position for a neglected childhood age group8
Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults8
The zebrafish as a potential model for vaccine and adjuvant development8
Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers8
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review8
The use of electroporation to deliver DNA-based vaccines8
Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study8
The broader socio-economic value of adult respiratory disease vaccinations in the UK – results from a benefit cost analysis8
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study8
Adverse events following influenza immunization: understanding the role of age and sex interactions8
Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate8
Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India8
Human lymph node immune dynamics as driver of vaccine efficacy: an understudied aspect of immune responses8
Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs8
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial8
Control measures for neglected tropical diseases: vaccine updates7
A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations7
Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies7
Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights7
Novel approaches to reactivate pertussis immunity7
A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia7
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis7
Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong7
Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis7
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England7
Vaccination coverage rates and attitudes towards mandatory vaccinations among healthcare personnel in tertiary-care hospitals in Greece7
Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital7
Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children7
Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland7
Current vaccine approaches and emerging strategies against herpes simplex virus (HSV)7
A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children7
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews6
Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis6
Eliminating nonmedical exemptions: a radical shift in how childhood vaccine mandates govern6
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines6
Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities6
COVID-19 vaccines: the start of a new era in regulation?6
The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing6
The potential of intrinsically disordered regions in vaccine development6
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity6
The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and met6
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine6
GMMA as a ‘plug and play’ technology to tackle infectious disease to improve global health: context and perspectives for the future6
Immune mechanisms targeting malaria transmission: opportunities for vaccine development6
Typhoid conjugate vaccines: is a single dose enough for durable protection?6
Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?6
Clinical development and approval of COVID-19 vaccines6
0.05401611328125